Methods and systems for providing a nutraceutical program specific to an individual animal

ABSTRACT

The present invention relates to methods and systems for providing an animal with a nutraceutical program that is specifically tailored to address the deficiencies and/or needs of the particular animal. Blood is drawn from the animal and analyzed at a lab to obtain blood test results. The blood test results are scored to obtain at least one blood test score for at least one corresponding blood parameter. If the at least one blood test score falls within a normal range but outside of an optimal range, one or more nutraceuticals needed to bring the animal within the optimal range for the at least one corresponding blood parameter are identified. A prescribed dosage amount is then calculated for at least one of the one or more identified nutraceuticals for the animal. The calculation of the prescribed dosage amount is based on at least the blood test score for the corresponding blood parameter and a deviation of the blood test score from the optimal range.

This application is a continuation-in-part of commonly-owned, co-pendingU.S. patent application Ser. No. 12/157,106 filed on Jun. 6, 2008, whichis a divisional of U.S. patent application Ser. No. 11/228,571 filed onSep. 15, 2005 (now U.S. Pat. No. 7,409,297 issued on Aug. 5, 2008), andwhich claims the benefit of U.S. Provisional Patent Application No.60/610,748, filed Sep. 17, 2004, each of which is incorporated hereinand made a part hereof by reference.

BACKGROUND OF THE INVENTION

The present invention relates to methods and systems for providing anutraceutical program specific to an individual animal. Moreparticularly, the present invention enables an assessment of the healthof internal organs of an animal, and the available vitamins, mineralsand enzymes required for the metabolic processes. Using blood resultsand medical history, the Nutritional Blood Test (NBT) provided by thepresent invention prioritizes the nutrients required to optimize organfunction and balance metabolism. It then matches the results to specificnutraceuticals that support a clinical response.

An animal's organs and glands, though not considered pathological, maynonetheless be functioning less than optimally. There may be underlyingweaknesses, deficiencies or imbalances, which if left unchecked, maydegenerate into a disease process.

Standard blood testing focuses strictly on pathology and often fails toexpose metabolic and physiological weaknesses. While blood testing iscustomarily the first step toward diagnosis, the need exists for ananalysis that distinguishes organ weaknesses rather than simplyidentifying “normals” and “abnormals.” The orientation needs to beexpanded from “what organs are not functioning” to “how the organsshould be functioning.”

In the past, the standard treatment was to provide medical andnutritional supplements to animals to maintain or restore their health.One prior art method of providing nutraceuticals to animals is in theform of multivitamins wherein a predetermined amount of nutritionalsupplements are administered, without variation, for a given set ofanimals. In such a method, the specific nutritional deficiencies of theindividual animal are not addressed.

Other prior art methods have been developed for providing nutritionalsupplements to animals. However, none of these prior art methods providefor analyzing an animal and prescribing a nutraceutical programspecifically tailored for that particular animal based on the analysis.In particular, the prior art does not provide for prescribing anutraceutical program specifically tailored to address deficiencies ofan animal, in terms of identifying desired nutraceuticals andcalculating dosages for the identified nutraceuticals for treating suchdeficiencies in order to optimize the health of the animal. Further, theprior art does not disclose a method for optimizing the health of ananimal which has blood scores in the normal range but which may stillhave some specific inadequacies.

Accordingly, there is a need in the art for more refined methods andapparatus that can determine specific nutritional deficiencies of ananimal that tests within a “normal” range. Therefore, it is an object ofthe present invention to provide methods and systems for customizedtreatment of animals. It is another object of the present invention toprovide methods and systems for customized treatment of animals based onblood analysis. It is a further object of the present invention toprovide methods and systems of treating animals, tailored to individualanimals, based on blood analysis of the animals. It is an additionalobject of the present invention to provide methods and systems fortreating animals that may lack certain nutrients. It is still a furtherobject of the present invention to provide methods and systems fortreating animals that have organs that are not functioning optimally.

It is an additional object of the present invention to provide methodsand systems for treating animals, which tailors composition and dosagesof neutraceuticals to the specific needs of an individual animal. It isstill a further object of the present invention to provide methods andsystems for veterinarians to forward an animal's blood work to a lab,and in response thereto, to receive a treatment recommendation. It is afurther object of the present invention to provide methods and systemswhich enable a veterinarian to interact with a provider of nutraceuticaltreatment plans via a communications network, such as the Internet.

The methods and systems of the present invention provide the foregoingand other advantages.

SUMMARY OF THE INVENTION

The present invention relates to methods and systems for providing anutraceutical program specific to an individual animal. The presentenables a detailed assessment of the health of internal organs of ananimal, as well as the available vitamins, minerals and enzymes requiredfor the metabolic process. The methods and systems of the presentinvention prioritize the nutrients required to optimize organ functionand to balance metabolism. The present invention identifies the specificnutraceuticals, and determines specific dosages thereof, in response tothe assessment. The present invention is useful in identifying thedeficiencies or imbalances of an animal due to poor nutrient absorptionand utilization, and provides a treatment responsive thereto,specifically tailored to an individual animal.

In an example embodiment of the present invention, a method of providinga nutraceutical program specific to an individual animal is provided.Blood is drawn from the animal and analyzed at a lab to obtain bloodtest results. The blood test results are scored to obtain at least oneblood test score for at least one corresponding blood parameter. It canthen be determined whether the at least one blood test score fallsoutside a normal range defined for the corresponding blood parameter. Anoptimal range within the normal range is also defined for each bloodparameter. If the blood test score(s) for the at least one correspondingblood parameter are within the optimal range(s), the animals health isoptimal and no nutraceuticals are prescribed for the animal.

If the at least one blood test score falls within the normal range butoutside of the optimal range, one or more nutraceuticals needed to bringthe animal within the optimal range for the at least one correspondingblood parameter are identified. A prescribed dosage amount is thencalculated for at least one of the one or more identified nutraceuticalsfor the animal. The calculation of the prescribed dosage amount is basedon at least the blood test score for the corresponding blood parameterand a deviation of the blood test score from the optimal range.

If the at least one blood test score falls outside of the normal range,it is determined that the animal is ill, and standard nutrients ormedications are prescribed in order to bring the at least one blood testscore within the normal range.

In one example embodiment, the animal may comprise a human. In anotherexample embodiment, the animal may comprise a fish, an amphibian, areptile, a bird, or a mammal. Alternatively, the may belong to one ofthe following groups of animals: livestock, cattle, pets, domesticatedanimals, zoo animals, or exotic animals.

The identification of the one or more nutraceuticals may be based on atleast one of animal type, animal physiology, animal biochemistry, datadescribing an observed physical condition of the animal, data describinga medical diagnosis of the animal, and the like.

The calculation of the prescribed dosage amount for a particularidentified nutraceutical may comprise calculating a “pre-cap” dosageamount based on the blood test score, the deviation of the at least oneblood test score from the optimal range, animal type, animal weight,dosage strength information, and dosage limit information. Thecalculated pre-cap dosage amount may then be compared to a “low-cap”dosage amount and a “high-cap” dosage amount for the particular animal.If the pre-cap dosage amount is between the low-cap and high-cap dosageamounts, the prescribed dosage amount is equal to the pre-cap dosageamount. If the pre-cap dosage amount is greater than the high-cap dosageamount, the prescribed dosage amount is equal to the hi-cap dosageamount. If the pre-cap dosage amount is less than the low-cap dosageamount, the prescribed dosage amount is equal to the low-cap dosageamount.

The low-cap dosage amount is the minimum amount of an identifiednutraceutical prescribed for an animal regardless of the animal weightor the deviation of the at least one blood test score from the optimalrange. The high-cap dosage amount is the maximum amount of an identifiednutraceutical prescribed for an animal regardless of the animal weightor the deviation of the at least one blood test score from the optimalrange.

In one example embodiment of the present invention, the pre-cap dosageamount may be equal to a dosage strength S times the weight of theanimal. The dosage strength S may be defined as:

S=slope(blood score−maximum range value)+High dosage.

A plurality of severity levels indicating a range of blood test scoreswhich deviate from the optimal range may be established. A negativeseverity level may indicate a range of blood test scores below a minimumof the optimal range, and a positive severity level may indicate a rangeof blood test scores above a maximum of the optimal range.

If the at least one blood test score falls within a negative severitylevel, then the maximum range value is the highest value of the negativeseverity level closest to the optimal range and a minimum range value isthe lowest value of the negative severity level furthest from theoptimal range. If the at least one blood test score falls within apositive severity level, then the maximum range value is the highestvalue in the positive severity level furthest from the optimal range andthe minimum range value is the lowest value in the positive severitylevel closest to the optimal range.

The slope may then be defined as:

slope=(high dosage−low dosage)/(maximum range value−minimum rangevalue).

The low dosage may indicate a minimum nutraceutical strength prescribedfor an animal regardless of the animal weight or the severity level ofthe at least one blood test score. The high dosage may be approximatelydouble the low dosage.

At least one of the normal range and the optimal range may be derivedfrom a database containing historical blood test scores for a pluralityof animals. The database may be updated with information regarding theanimal type, the animal weight and the blood test scores.

The blood parameters measured in the blood test analysis may comprise atleast one of white blood cell information, red blood cell information,and blood chemistry information. The blood parameters may correspond tothe function of one or more organs of the animal. For example, the bloodparameters measured during the blood test may include one or more of thefollowing: AST (SGOT), ALT (SGPT), total bilirubin, alkalinephosphatase, GGTP, total protein, albumin, globulin, A/G ratio,cholesterol, urea nitrogen (Bun), creatinine, BUN/creatinine ratio,phosphorus, calcium, glucose, amylase, lipase, sodium, potassium,chloride, CPK, triglycerides, lactic dehydrogenase, white blood cellcount, red blood cell count, hemoglobin (HGB), hemactocrit (PCV, HCT),absolute polys (neutrophils), absolute lymphocytes, absolute monocytes,absolute eosinophils, platelet count, T4, and the like.

The nutraceuticals may comprise at least one of vitamins, minerals,enzymes, amino acids, homeopathic supplements, herbal supplements, rawglandular supplements, and the like.

The blood test results may be electronically communicated from the labto a service provider. The service provider may score the blood testresults to obtain the at least one blood test score. The serviceprovider may also calculate the prescribed dosage amounts of theidentified nutraceuticals. The prescribed dosage amounts may beelectronically communicated from the service provider to a compoundpharmacist. The compound pharmacist may then prepare a prescriptioncontaining the one or more identified nutraceuticals in accordance withthe prescribed dosage amounts and ship the prescription to an owner ofthe animal or veterinarian for administration to the animal.

The present invention also provides for systems for implementing theabove-described methods. In particular, the present inventionencompasses a system for providing a nutraceutical program specific toan individual animal. In an example embodiment of such a system inaccordance with the present invention, a blood analyzer is provided foranalyzing a blood sample of an animal to obtain blood test results. Inaddition, a database is provided which contains historical blood testscores for a plurality of animals. The historical blood test scoresdefine normal ranges for corresponding blood parameters and definecorresponding optimal ranges within the normal ranges for thecorresponding blood parameters. A processor in communication with theblood analyzer and the database is also provided as part of the system.The processor may be adapted to: score the blood test results to obtainat least one blood test score for at least one corresponding bloodparameter and determine if the at least one blood test score fallsoutside the normal range defined for the corresponding blood parameter.If the at least one blood test score falls within the normal range butoutside of the optimal range, the processor may identify one or morenutraceuticals needed to bring the animal within the optimal range forthe at least one corresponding blood parameter. Once thenutraceutical(s) are identified, the processor may then calculate aprescribed dosage amount for at least one of the one or more identifiednutraceuticals for the animal. The calculation of the prescribed dosageamount may be based on at least the blood test score for thecorresponding blood parameter and a deviation of the blood test scorefrom the optimal range.

If the at least one blood test score falls outside of the normal range,it is determined that the animal is ill, and standard nutrients ormedications are prescribed for the animal in order to bring the at leastone blood test score within the normal range.

The processor identifies one or more nutraceuticals based on at leastone of animal type, animal physiology, animal biochemistry, datadescribing a physical condition of the animal, and data describing amedical diagnosis of the animal. The data used by the processor may beobtained from the database or input via a user terminal, such as apersonal computer, personal digital assistant, cellular telephone,laptop computer, or the like. Such data may be directly input via a userterminal directly connected to the processor or via a user terminalremotely linked to the processor via a wired or wireless communicationnetwork, such as the Internet, a wide area network, a local areanetwork, a global area network, a telephone network, or the like,including any combination of such networks. Those skilled in the artwill appreciate that the processor may also be in communication withmore than one database containing the required information.

The processor may calculate the prescribed dosage amount for aparticular identified nutraceutical using the formulas arid methodsdiscussed above.

The database(s) may also store information regarding the severity levelsdiscussed above, which indicate ranges of blood test scores whichdeviate from the optimal range (e.g., the negative and positive severitylevels discussed above).

The blood test results may be electronically communicated from the bloodanalyzer at a lab to the processor at a service provider. The prescribeddosage amounts calculated by the processor may then be electronicallycommunicated from the service provider to a compound pharmacist. Thecompound pharmacist can then prepare a prescription containing the oneor more identified nutraceuticals in accordance with the prescribeddosage amounts and ship the prescription to an owner of the animal or aveterinarian for administration to the animal.

The features discussed above in connection with the example embodimentsof the methods of the present invention are equally applicable to thesystem embodiments of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will hereinafter be described in conjunction withthe appended drawing figures:

FIG. 1 (FIGS. 1A and 1B) shows a block diagram of an example embodimentof the present invention; and

FIG. 2 shows a flow chart of an example embodiment of a NutraceuticalGeneration Process used in connection with the present invention.

DETAILED DESCRIPTION

The ensuing detailed description provides exemplary embodiments only,and is not intended to limit the scope, applicability, or configurationof the invention. Rather, the ensuing detailed description of theexemplary embodiments will provide those skilled in the art with anenabling description for implementing an embodiment of the invention. Itshould be understood that various changes may be made in the functionand arrangement of elements without departing from the spirit and scopeof the invention as set forth in the appended claims.

The present invention provides methods and systems for providing anutraceutical program specific to an individual animal. In accordancewith an example embodiment of the present invention, an animal's bloodis taken and an analysis is performed thereon. The blood test is scoredto determine whether it is normal or abnormal. An abnormality isnormally indicative of a disease. In response to an abnormality,“off-the-shelf” nutrients, typically in the form of capsules, areprovided for the animal. Results for an animal in the normal range areanalyzed to determine whether there are any nutritional deficiencies.With this process, treatments are tailored to the individual animal interms of the nutraceuticals to be taken by the animal.

In one example embodiment, the animal may comprise a human. In anotherexample embodiment, the animal may comprise a fish, an amphibian, areptile, a bird, or a mammal. Alternatively, the may belong to one ofthe following groups of animals: livestock, cattle, pets, domesticatedanimals, zoo animals, or exotic animals. The methods and systems of thepresent invention can be adapted for use with most animal types.

There are typically ranges of blood test scores for each measured bloodparameter that are suitable for a healthy (i.e., “normal”) animal.However, within these normal ranges, there are subtle gradations oftissue integrity and organ efficiency that can be measured and that arean important component of wellness and healing. The present inventionlooks beyond the reference range (normal range) to a level ormeasurement that highlights how an organ or system is performing. Inother words, the present invention enables the selection of nutrientsfor optimizing overall health and organ function for even a healthyanimal.

Essentially, the present invention seeks to provide treatment to bringan animal into an optimal range, which exists within a normal referencerange. The optimal range is defined as the more narrow normal range inwhich organs or metabolic processes are functioning at peak efficiency.Within the optimal range there is no degradation and no need forcorrective measurements. However, results outside the optimal range,while not necessarily indicating a disease or abnormality, do indicatethat a particular organ system may not be functioning at optimalefficiency and therefore, may require corrective support.

The blood test results of an animal are analyzed and it is determinedwhether the blood test scores fall within the optimal ranges establishedfor particular blood parameters. An assessment is made of the status ofspecific organs, along with a determination of stored and availablelevels of vitamins, minerals and enzymes. In response to these results,a nutritional program specific to the animal is recommended for theanimal.

The nutrients or nutraceuticals considered for use in connection withthe present invention may include vitamins, minerals, enzymes, aminoacids, homeopathic supplements, herbal supplements, raw glandularsupplements, and the like. These nutrients are specifically blended tomatch the deficiencies found in the animal's blood and are preciselydosed according to the animal's weight and severity of the imbalances ordeficiencies. The nutrient combination may be provided in powder orliquid form as desired. Providing such custom tailored dosageseliminates the need for pre-formulated capsules and tablets, and endsthe challenges of administering multiple tables and capsules. Whennecessary or at the request of the attending veterinarian, the nutrientcombination can be made up in capsule or tablet form. Additionally,inert compounds, such as binders, fillers, coatings, preservatives,coloring agents and additives, which often increase the risk ofintestinal inflammation or interference with the absorption offat-soluble vitamins, are eliminated by the present invention.Advantageously, custom blended powders are more bio-available andthereby maximize assimilation and minimize gastrointestinal discomfort.Further, overdosing is eliminated, as precise quantities are provided.

From the perspective of a veterinarian, the present invention mayinvolve the following steps:

1. Drawing blood for a Complete Blood Count (CBC), Super Chem blood test(also referred to as the complete blood chemistries, SMA, or CHEMProfile), and a Thyroid Test (T4), or the like;

2. Completing a questionnaire and affixing tracking stickers from aBlood Testing Laboratory Diagnosis (Request or Accession) Form to theblood vials;

3. Scheduling pick-up of the blood by a Blood Testing Laboratory;

4. Receiving a report from the lab highlighting imbalances and/ordeficiencies, and outlining the recommended responsive therapy; and

5. Receive prescribed dosages of nutraceuticals from compoundpharmacist.

From the perspective of the service provider that provides theNutritional Blood Test of the present invention, the blood testing laband the compound pharmacist center, the present invention may involvethe following steps:

1. Receiving a blood sample from an animal with the correspondingmedical history of the animal including age, sex, breed, weight, currentmedications, supplementation and diet, vaccination history, medicaldiagnosis information, and the like;

2. Analyzing the blood specifically for information relating to the redblood cells, white blood cells and blood chemistries;

3. Scoring the blood; which may include taking the results of at leastone of a Complete Blood Count (CBC), a Super Chem blood test (alsoreferred to as the complete blood chemistries, SMA, or CHEM Profile), aThyroid Test (T4), or the like, and scoring the results of one or moreof these tests in relationship to a deviation from optimal;

4. Comparing the scores to a database:

5. Determining if and where the scores deviate from optimal;

6. Determining the nutraceuticals needed (as determined from thephysiological analysis of the blood with the end goal of bringing theanimal to optimal); and

7. Determining proper dosage (of nutrients, nutraceuticals and remedies)for the animal; and

8. Utilizing a Compounding Pharmacist, preparing proper dosages ofspecific nutraceuticals specifically tailored to the animal.

The term “nutraceuticals” as used herein is meant to encompass vitamins,minerals, glandular supplements, medicinals, enzymes, amino acids,nutrients, homeopathic supplements, herbal supplements, and the like.The nutraceuticals may generally be prescribed on two to three monthsupplemental programs (for severe cases, week-to-week or monthlyregimens are prescribed). After the initial period, the blood test(s)may be repeated and a follow-up analysis may be performed. Thedeficiencies and imbalances are re-evaluated and compared to theoriginal NBT analysis and, based upon the progress, the supplementationprogram is adjusted. (Either enhanced, kept the same, or reduced to amaintenance level based upon the blood results and the animal's clinicalcondition and level of improvement.)

As a result of looking up blood scores manually and prescribingsupplements to correct deficiencies over approximately the past 25years, data has been correlated and a computer model has been developed.In a preferred embodiment, the computer analysis provided by the presentinvention evaluates approximately 36 different blood score factors andcompares them to reference ranges developed over years of testing. Theoptimal ranges of the present invention are developed from thishistorical data, based upon the clinical importance of the individualblood test and what the blood test indicates physiologically andbiochemically. The present invention then factors in characteristicsabout the animal such as size and weight and creates an individualtreatment program for an animal, which identifies nutrients and dosages.The treatment program is therefore specifically customized for theanimal and the animal is provided with exactly the treatment needed tooptimize the animal's health.

FIG. 1 is a block diagram of an example embodiment of the presentinvention. Initially, a veterinarian submits a blood sample (shown at 1)from a veterinarian hospital 20 to a blood testing laboratory 22. Theblood sample submission 1 is received at the blood testing laboratory22(shown at 2). The received blood sample 2 from the veterinarian may belabeled for identification and tracking purposes at a receiving station12. The blood sample submission 1 may be accompanied by an NBT(Nutritional Blood Test) Questionnaire developed in accordance with thepresent invention. Alternatively, the blood testing laboratory 22 maysend the NBT Questionnaire or Blood Test Request or Accession Form tothe veterinarian hospital 20 by fax or otherwise. The NBT Questionnaireincludes specific information about the animal, including but notlimited to the Weight, Age, Sex Breed, Species, and clinical and medicalhistory concerning the animal. Once the veterinarian has provided thecompleted NBT Questionnaire, the Questionnaire is labeled at the BloodTesting Laboratory and is kept with the blood vials that were submitted.Tracking stickers may be provided on the Questionnaire, which trackingstickers can be affixed to the blood vials for tracking purposes.

The blood testing laboratory 22 performs a blood analysis (e.g., atblood analyzer 23) pursuant to the present invention and the results canbe printed and/or sent or faxed to the veterinarian. The results of theblood test are posted (shown at 21). The Report sent to the veterinarianmay include the blood results of at least one of a Complete Blood Count(CBC), Super Chem blood test (or the complete blood chemistries), and aT4 test for the veterinarian's medical evaluation. The results of thetest(s) and corresponding paperwork including the NBT Questionnaire arealso stored on a database 26 at the blood testing laboratory 22, whichis in communication with server 24 located at the blood testinglaboratory 22. At designated intervals, a web service 25 (operated bythe service provider 30) polls this server 24 to check for new data.When a new test is found, the data is then encrypted and transferred(shown at 3) (e.g., using TCP/IP) to a web service 31 on the main server32 at the service provider 30 (e.g., such as Bionutrional, LLC, theassignee of the present invention) at which point the data isunencrypted and transferred (shown at 4) to and stored in the primarydatabase 34 located at the service provider 30. Those skilled in the artwill appreciate that, although FIG. 1 shows a database 26 located at theblood testing laboratory 22 and a database 34 located at the serviceprovider 30, the functions of these two databases may be combined into asingle database, which may be located at a remote location with acorresponding database server, or at either the service provider 30 orthe blood testing laboratory 22. In either case, the blood testinglaboratory 22 and/or the service provider 30 may communicate with such acombined database via conventional methods, such as via the Internetusing a web browser, or over a local area network or a wide areanetwork, as is known in the art.

A monitoring device 37 monitors new data loaded into the serviceprovider database 34, and triggers an event, which notifies the serviceprovider 30 that a new blood test has been sent from the blood testinglaboratory 22. Thereafter, based upon the NBT Questionnaire (medicalhistory, diagnosis and drugs being used) and the physiological analysisof the blood, the service provider 30 conducts a nutritional andphysiological analysis (e.g., at processor 36) to determine the optimumrange and the selection and calculation of the specific nutraceuticalsthat will be custom blended for the animal. It should be appreciatedthat the processor 36 selects a particular nutraceutical ornutraceuticals for each blood parameter based on a number of factors,which factors include but are not limited to the severity of thedeficiency, the type of animal, the sex of the animal, the weight of theanimal, historical treatment data, known associations between specificnutraceuticals and blood parameters, physiological data obtained fromthe blood analysis, animal physiology, animal biochemistry obtained fromthe blood analysis, data describing an observed physical condition ofthe animal, data describing a medical diagnosis of the animal, and thelike. This selection process may be governed by “rules” which enable theprocessor 36 to take into account the foregoing factors when selecting aparticular nutraceutical. Further, the rules and the inter-relationshipsbetween the particular factors used are continuously updated based onnew data acquired through the testing and monitoring enabled by thepresent invention, such that the processor 36 is able to continuallyrefine the selection process over time.

The calculated prescription may forwarded for review and approval (shownat 5) to a quality control station 39 at the service provider 30. Areport containing the blood results, interpretation of the results,recommended therapy (e.g., nutraceutical dosages and schedule foradministration of same), follow-up schedule and order form is thencommunicated (shown at 6) to the veterinarian for review bycommunications means 38, for example via the Internet 70, email, regularmail, or any other communication means and received by correspondingcommunication means 17 at the veterinarian hospital 20. Order approvalcan also be sent and order status checked by communication device 16 atthe veterinarian hospital, which is in communication with the webservice 31 of the service provider 30.

Upon receiving approval 40 of the Report from the veterinarian hospital20 (via telephone, Internet, facsimile, email, or any othercommunications means 18), the veterinarian places an order (shown at 7)with the service provider. An order is generated through software 45(referred to Nutritional Therapy Processing System software) at theservice provider 22 and a notification (shown at 8) of the order is sentto the Compounding Pharmacist 50 that an order has been placed and isready for processing. The Compounding Pharmacist 50 utilizes thecorresponding software 51 to view the order. The compound pharmacist 50may be in communication with the service provider 30 via communicationmeans 54 and Windows Service 55. After processing the order (e.g., atCPU 52), the Compounding Pharmacist 50 sends a notification (shown at 9)to the service provider 30 via communication means 54 that the order hasbeen shipped and is ready for invoicing. The service provider 30monitors shipped orders (e.g., at monitor 44) and generates an invoice(shown at 10) which is sent to the veterinarian hospital 20. The bloodtesting laboratory 22 may also generate an invoice for the blood testingservices provided (e.g., via billing system 60) and send this invoicedirectly to the veterinarian hospital 20. Alternatively, the bloodtesting laboratory 22 may bill the service provider 30, who in turnspasses the costs of the blood test on to the veterinarian hospital 20 inthe invoice shown at 10.

At any time, veterinarians can log into the service provider web site11, access their own private area where they can view their patient'sNBT reports, check the status of orders 19 and view a history of theirorders and reports. A Status Web Service 15 connected to server 32enables the veterinarian to obtain status information on orders. In thepublic area of the website, visitors can find out more about theNutritional Blood Test and integrating nutrition with patient care.

Those skilled in the art will appreciate that the example describedabove and shown in FIG. 1 is only one example implementation of thepresent invention, and that the entire process encompassed by thepresent invention may be implemented by a single service provider at asingle location. In other words, the service provider may provideveterinary services, blood testing services, blood analysis, thedetermination of required nutraceuticals, the determination ofprescribed dosages, and compounding pharmacist's services at a singlelocation. Alternatively, the steps of the present invention may beprovided by one or more entities or individuals at one or moredistributed locations. These locations may be interconnected by anetwork, such as one or more of a telephone network, the Internet, alocal area network, a wide area network, a wired or wireless network, orany combination thereof.

FIG. 2 shows a flowchart of an example embodiment of the NutraceuticalGeneration Process of the present invention, which determines the properdosages for each nutraceutical prescribed. The process begins with bloodchemical readings (step 1) that are the result of tests that areconducted for numerous blood score factors. A sample of blood testscores for various blood test parameters is shown in Table 1 below. Theexample scores shown in Table 1 are for a canine blood sample. Table 1shows the actual breakdown of the individual blood scores for eachmeasured blood parameter as they deviate from an optimum range willdetermine what they will mean nutritionally. Each blood score iscompared with the normal and optimal ranges determined for thatparticular blood parameter.

TABLE 1 Sample Blood Test Scores for Canine Blood Parameters OutsideNormal Not Reference Optimum (Chemistries) Normal Optimal Optimal RangeRange AST (SGOT) 43 15-66 28-53 ALT (SGPT) 126  12-118 39-77 TotalBilirubin 0.2 0.1-0.3 0.1-0.3 Alkaline Phosphatase 664  5-131  37-100GGTP 7  1-12   3-4.5 Total Protein 6.7   5-7.4   6-6.8 Albumin 2 1.6-6.02.7-3.6 Globulin 2.8 1.6-3.6 2.1-3.1 A/G Ratio 1.4 0.8-2   1.1-1.7Cholesterol 300  92-324 135-266 Urea Nitrogen (BUN) 23  6-25 14-19Creatinine 1.8 0.5-1.6 0.8-1.3 BUN/Creatinine Ratio 13  4-27 10-21Phosphorus 4.9 2.5-6   3.4-5.1 Calcium 10.1  8.9-11.4  9.5-10.8 Glucose79  70-138  70-183 Amylase 969  290-1125 499-916 Lipase 420  77-695232-541 Sodium 150 139-154 143-150 Potassium 5.6 3.6-5.5 4.1-5  Chloride 109 102-120 107-116 CPK 155  59-895 268-686 Triglycerides 147 29-291  95-226 Lactic Dehydrogenase 180  20-500 140-380 WBC (WhiteBlood Cells) 11.9   4-15.5  6.9-12.6 RBC (Red Blood Cells 5.3 4.8-9.35.93-8.18 Hemoglobin (HGB) 12.8 12.1-20.3 14.2-18.3 Hematocrit (PCV,HCT) 38 36-60 42-54 Absolute Polys 7259  2060-10600 4195-8465(Neutrophils) Absolute Lymphocytes 2380  690-4500 1643-3548 AbsoluteMonocytes 833  0-840 210-790 Absolute Eosinophils 1428   0-1200  50-900Platelet Count 389 170-400 228-343 T4 1.87 1-4 1.6-4  

Note that the optimal range for glucose is 70-183, while the normalrange for glucose is 70-138, which is the only parameter for which theoptimal range is outside of the normal range. The normal range forglucose is set outside of the normal range on the high end to compensatefor elevated glucose levels present in the blood immediately aftereating.

From Table 1 it can be seen that the blood test scores for albumin, ureanitrogen (BUN), creatinine, alkaline phosphatase, ALT (SGPT),cholesterol, potassium, amylase, CPK, GGTP, hemoglobin (HGB), hematocrit(PVC, HCT), red blood cell count, absolute monocytes, absoluteeosinophils, and platelet count fall either within the normal range butoutside of the optimal range or fall outside of the normal rangealtogether. The remaining measured blood parameters in the Table 1example fall within the optimal range. The scores for the bloodparameters that fall outside of normal (ALT (SGPT), alkalinephosphatase, creatinine, potassium, and absolute eosinophils) may beindicative of a disease and may be treated with prescriptionmedications. An interpretation of the blood test scores of Table 1 thatfall outside the optimal and normal ranges is provided below.

The blood test score for albumin is 2, which is normal but belowoptimum. A depressed ALBUMIN level may indicate insufficient or poorquality protein in the diet. It may also indicate a degenerative diseaseand wasting or a sluggish metabolism of the liver. This often indicatesthe requirement for liver supplements, certain B vitamins, Vitamins A,C, and D, amino acids, and lecithin.

The blood test score for urea nitrogen (BUN) is 23, which is normal butabove optimal. An elevated BUN level indicates an overload of the liverand kidneys as well as weaknesses in the pituitary, thyroid and liver,which oversee protein metabolism. This overload may indicate adeficiency of important minerals such as magnesium, copper, iodine andiron. It may also indicate serious kidney disease.

The blood test score for creatinine is 1.8, which is above the normalrange. An elevated creatinine level indicates impaired metabolism in themuscles as well as improper protein absorption. This may indicateweaknesses in the pancreas leading to low levels of pancreatic enzymesas well as weaknesses in the anterior pituitary and gonadal system. Thismay also indicate serious kidney disease.

The blood test score for alkaline phosphatase is 664, which is above thenormal range. An elevated alkaline phosphatase level indicates theinefficient movement of minerals throughout the body. This may indicatethat the glands are too acidic as compared to the blood. This may alsoindicate hyperactivity and an underlying weakness in the adrenals andthe gonadal system. It may also indicate the requirement for acidicnutrients such as vitamin C (ascorbic acid), PABA, pantothenic acid, andfolic acid as well as important minerals, sodium and potassium. Longstanding elevated levels can be associated with weaknesses of theadrenal glands (called Cushing's Disease) as well as the presence ofserious degenerative disease such as cancer. Elevated levels are commonin rapidly growing kittens and puppies, or when a fractured bone ishealing.

The blood test score for ALT (SGPT) is 126, which is above the normalrange. An elevated alanine transferase level may indicate a weakness ordisease of the liver. This also may indicate deficiencies of vitamin A,vitamin D and vitamin B6 as well as iron, copper and iodine. Elevatedlevels may also indicate an exposure to toxic chemicals or pollutants.

The blood test score for cholesterol is 300, which is normal but aboveoptimal. An elevated cholesterol level may indicate higher than desiredlevels of saturated fats in the diet (as found in most commercial petfoods). These saturated fats stimulate the absorption of all fats ingeneral, including cholesterol. This may cause the blood to thicken andpredispose oxidation of these blood fats (rancidity). This indicates theneed for lecithin, choline and inositol and trace and essentialminerals. This may also indicate an overall weakness in the anteriorpituitary as well as an imbalance in the acid levels of the stomach andintestines.

The blood test score for potassium is 5.6, which is above the normalrange. An elevated potassium level may indicate a weakness as well asexcessive breakdown of heart muscles, which may lead to irregularcontractions. This may indicate the requirement for vitamin E, coenzymeQ10 and the amino acid L-carnitine.

The blood test score for amylase is 969, which is normal but aboveoptimal. An elevated amylase level indicates an active inflammation inthe pancreas, which may represent a weakened pancreas or in some casesmay require medical treatment (acute pancreatitis). Diet should beadjusted to lower intake of fat, and to properly balance the levels ofessential fatty acids, highly digestible proteins and complexcarbohydrates.

The blood test score for CPK is 155, which is normal but below optimal.A depressed creatine phosphokinase level may indicate atrophy or wastingof the muscles, including the muscles. of the heart. This may alsoindicate deficiencies of essential amino acids and vitamin E.

The blood test score for GGTP is 7, which is normal but above optimal.An elevated gamma glutamyl transferase level indicates a decrease inoxygen levels in the body due to the presence of excessive wastes andtoxins. This may indicate deficiencies of vitamin B complex, copper andiron. This may also indicate weaknesses in the liver.

The blood test score for hemoglobin (HGB) is 12.8, which is normal butbelow optimal. A depressed hemoglobin level indicates anemia,malnutrition and/or improper absorption of food into the blood. This mayindicate weaknesses in the liver and spleen as well as deficiencies ofvitamin B complex, vitamin C and iron as well as the requirement forhighly-digestible proteins and amino acids.

The blood test score for Hematocrit (PCV, HCT) is 38, which is normalbut below optimal. A depressed hematocrit level indicates less thandesired levels of red blood cells (anemia). This may indicate weaknessesin the bone marrow, liver and spleen, as well as deficiencies of vitaminB12 and iron.

The blood test score for RBC (Red Blood Cells) is 5.3, which is normalbut below optimal. A depressed red blood cell count indicates a loss ofblood or the body's inability to manufacture adequate levels of redblood cells (anemia). This may indicate higher than desired levels ofwastes or toxins in the blood, an adverse reaction to drugs, or thepresence of a chronic degenerative condition. This may also indicateweaknesses in the liver, bone marrow, spleen and liver as well as therequirement for vitamin B12, chlorophyll and iron.

The blood test score for Absolute Monocytes is 833, which is normal butabove optimal. An elevated monocyte count indicates the presence oflonger-standing infection and inflammatory processes. This may indicatethe requirement for vitamin C, vitamin A and vitamin E.

The blood test score for Absolute Eosinophils is 1428, which is abovenormal. An elevated eosinophil count indicates an allergic condition orthe presence of such parasites as heartworms or intestinal worms. Thismay indicate weaknesses in the thymus and adrenals. This may alsoindicate the requirement for vitamin B6 and vitamin C.

The blood test score for Platelet Count is 389, which is normal butabove optimal. An elevated platelet count may indicate thickening of theblood or an inflammation of the bone marrow. This may also indicate aweakness in the bone marrow, as well as deficiencies of vitamin C andvitamin E.

Once the blood test scores are obtained and it is determined whetherthey fall within the optimal range, within the normal range but outsideof optimal, or outside of the normal range, the specific nutraceuticalsrequired to bring the animal to optimal health can be determined. Asdiscussed above, different nutraceuticals may be required for each bloodparameter that falls outside of the optimal range. The requirednutraceuticals may also vary depending on whether the score falls aboveor below the optimal range.

For purposes of the example which follows, only the blood parameteralbumin is considered. As indicated in Table 1 above, the blood testscore for Albumin is 2, which is below the optimal range but within thenormal range. As indicated above, low albumin levels indicateinsufficient or poor quality protein in the diet. It may also indicate adegenerative disease and wasting or a sluggish metabolism of the liver.This often indicates the requirement for liver supplements, certain Bvitamins, Vitamins A, C, and D, amino acids, and lecithin. For purposesof the following example, the calculation of the required dosage of aliver supplement for low albumin levels will be determined. It should beappreciated that the same formulas and methods apply to thedetermination of the other nutraceuticals indicated by the low albuminlevel (i.e., vitamins A, C, and D, and lecithin), as well as to thenutraceuticals indicated by the other blood test scores that falloutside the optimal ranges corresponding thereto.

In accordance with the present invention, if the blood chemical readingsare determined to be outside of optimum range (step 2), they are groupedinto Severity Ranges (e.g., −1, −2, −3 and +1, +2, +3) based on how farthey deviate from optimum. Severity ranges may differ for each type ofanimal (canine, feline, equine, etc.). Each nutraceutical prescribed hasa set of dosage properties, an example of which is shown in Table 2below.

TABLE 2 CANINE DOSAGE CHART (Sample) (10) (25) (26) Type of Weight ofStrength Hi Low Ingredient Ingredient Frequency (Low Dosage) Cap CapEnzymes/Digestive Aids Bromelain Dry mg/lb w/food 1 200 20 Betaine HCLDry mg/lb w/food 1 200 20 Pancreatin Dry u/lb w/food 250 40,000 4,000Pepsin Dry mg/lb w/food 0.6 200 15 Glands Adrenal Dry mg/lb BID 2.65 50035 Bone Marrow Dry mg/lb BID 1.8 250 20 Brain Dry mg/lb BID 1.5 500 50Heart Dry mg/lb BID 2 500 50 Hypothalamus Dry mg/lb BID 0.35 35 5Intestines Dry mg/lb BID 2.1 600 35 Kidney Gland Dry mg/lb BID 2.65 50025 Liver Dry mg/lb BID 4.5 600 60 Lung Dry mg/lb BID 2.5 300 30 LymphDry mg/lb BID 1.5 300 30 Ovary/Uterus (Female Dry mg/lb BID 2 300 25Only) Pancreas Dry mg/lb BID 1.9 500 30 Parathyroid Dry mg/lb BID 0.0252.50 0.25 Pineal Dry mg/lb BID 0.025 10 1 Pituitary (Anterior) Dry mg/lbBID 0.75 125 15 Pituitary (Whole) Dry mg/lb BID 0.75 125 15Prostate/Testes (Male Dry mg/lb BID 2 300 25 Only) Salivary Dry mg/lbBID 0.8 125 35 Spleen Dry mg/lb BID 2.25 500 35 Stomach Dry mg/lb BID 2500 30 Thymus Dry mg/lb BID 2.65 600 35 Thyroid Dry mg/lb BID 0.8 250 15

The set of dosage properties shown in Table 2 is used in conjunctionwith Table 3 below, which shows an example of a Nutritional Blood Test(NBT) Worksheet (NBTW) for a canine. Table 3 is an example of a primarychart for calculating the proper dosages.

TABLE 3 NUTRITIONAL BLOOD TEST (NBT) WORKSHEET - CANINE (Sample) DOGWEIGHT: 75 (17) HIGH (16) DOSAGE (18) (19) (12) (13) (14) (15) LOWMULTI- MIN MAX (11) LOW HIGH NUTRA- BLOOD DOSAGE PLIER RANGE RANGE BLOODSEVERITY RANGE RANGE CEUTICAL CHEMICAL MULTI- (LOW VALUE VALUE CHEMICALRANGE VALUE VALUE SUPPORT READING PLIER DOSAGE × 2) (−3) (−1) ALBUMIN −31.6 1.9 Liver 2 4.5 9 1.6 2.6 Vitamin A/D 35 70 Vitamin C 6 12(Ascorbic) Vitamin C 6 12 (Ester) Vitamin B 1 2 Complex Lecithin 7.5 15Innositol Choline −2 2 2.3 Liver 4.5 9 Vitamin A/D 35 70 Vitamin C 6 12(Ascorbic) Vitamin C 6 12 (Ester) Vitamin B 1 2 Complex Lecithin 7.5 15Innositol Choline −1 2.4 2.6 Liver 4.5 9 Vitamin A/D 35 70 Vitamin C 612 (Ascorbic) Vitamin C 6 12 (Ester) Vitamin B 1 2 Complex Lecithin 7.515 Innositol Choline 0 2.7 3.6 OPTIMUM 0 RANGE 1 3.7 4.2 Salivary 0.81.6 Lecithin 7.5 15 Innositol Choline 2 4.3 4.5 Salivary 0.8 1.6Lecithin 7.5 15 Innositol Choline 3 4.6 6 Salivary 0.8 1.6 Lecithin 7.515 Innositol Choline (27) (22) (23) DOSAGE (20) (21) SLOPE STRENGTH (24)AMOUNT MIN MAX (HIGH DOSE − SLOPE × DOSAGE STRENGTH × (14) RANGE RANGELOW DOSE)/ (CHEM READING − AMOUNT WEIGHT BLOOD Revised VALUE VALUE (MAXRANGE − MAX RANGE) + STRENGTH × (HI/LOW CAP CHEMICAL Support (+1) (+3)MIN RANGE) HIGH DOSE) WEIGHT APPLIED) ALBUMIN Liver 3.7 6 4.5 6.3 472.5472.5 Vitamin A/D 35 49 3675 3675 Vitamin C 6 8.4 630 630 (Ascorbic)Vitamin C 6 8.4 630 630 (Ester) Vitamin B 1 1.4 105 105 Complex Lecithin7.5 10.5 787.5 787.5 Innositol Choline Liver 4.5 6.3 472.5 472.5 VitaminA/D 35 49 3675 3675 Vitamin C 6 8.4 630 630 (Ascorbic) Vitamin C 6 8.4630 630 (Ester) Vitamin B 1 1.4 105 105 Complex Lecithin 7.5 10.5 787.5787.5 Innositol Choline Liver 4.5 6.3 472.5 472.5 Vitamin A/D 35 49 36753675 Vitamin C 6 8.4 630 630 (Ascorbic) Vitamin C 6 8.4 630 630 (Ester)Vitamin B 1 1.4 105 105 Complex Lecithin 7.5 10.5 787.5 787.5 InnositolCholine OPTIMUM 0 0 0 RANGE Salivary 0.8 1.12 84 84 Lecithin 7.5 10.5787.5 787.5 Innositol Choline Salivary 0.8 1.12 84 84 Lecithin 7.5 10.5787.5 787.5 Innositol Choline Salivary 0.8 1.12 84 84 Lecithin 7.5 10.5787.5 787.5 Innositol Choline

Table 4 below provides a description of the terms used in Tables 2 and 3above. The numbers which precede each term in Table 4 below representthe numbered columns where the terms are used in Tables 2 and 3 above.

TABLE 4 Summary of Nutritional Blood Test Worksheet Terms andDescriptions (11) Severity: A general indicator of how far a chemicaltest deviates from normal. Severity levels range from −3 to +3 and eachlevel consists of a range of chemical readings. (12) Low Range Value:The minimum point of each Severity level. (13) High Range Value: Themaximum point of each Severity level. (14) Nutraceutical Support: Thenutraceuticals prescribed. (15) Blood Chemical Reading: The blood testscore from Blood Testing Laboratory. (16) Low Dosage Multiplier: Theminimum nutraceutical strength prescribed for an animal regardless ofweight or severity of blood analysis. (17) High Dosage Multiplier: Themaximum nutraceutical strength prescribed for an animal regardless ofweight or severity of blood analysis. High Dosage is usually twice theLow Dosage amount. (18) Min Range Value (−3): The lowest chemicalreading at the −3 Severity Level. (19) Max Range Value (−1): The highestchemical reading at the −1 Severity Level. (20) Min Range Value (+1):The lowest chemical reading at the +1 Severity Level. (21) Max RangeValue (+3): The highest chemical reading at the +3 Severity Level. (22)Slope: A multiplier used to calculate the strength of the dosageprescribed. Slope is derived from the following formula: (High Dosage −Low Dosage)/(Max Range − Min Range). (23) Strength: A number multipliedtimes the weight of an animal to determine the prescribed dosage.Strength is derived from the following formula: (Slope × (ChemicalReading − Max Range)) + High Dose). (24) Pre-Cap Dosage: The amountderived from multiplying the Strength times the weight of the animal.(25). Low Cap: The minimum Dosage Amount prescribed for an animalregardless of weight or severity of blood analysis. (26) High Cap: Themaximum Dosage Amount prescribed for an animal regardless of weight orseverity of blood analysis.

The first step in determining the proper dosage for a neutraceutical isto determine if the blood chemical reading 15 in Table 3 above is aboveor below the optimum range. If the blood chemical reading is belowoptimum (−1, −2, or −3 severity range), then the Minimum Range Value 18is the lowest reading in the −3 Severity Level and the Maximum RangeValue 19 is the highest reading in the −1 Severity Level. If the bloodscore is above optimum range (+1, +2, or +3 severity range), then theMinimum Range Value 20 is the lowest reading in the +1 Severity Leveland the Maximum Range Value 21 is the highest reading in the +3 SeverityLevel. Continuing the canine example as discussed above, a bloodchemical reading of 2 for the blood parameter albumin was obtained, asshown in column 15 of Table 3 above. A blood chemical reading of 2 fallswithin the −2 severity range (having a low range value of 2 shown incolumn 12 to a high range value of 2.3 shown in column 13) for albuminat column 11. In the Table 3 example shown, the optimum range (indicatedin column 14) for albumin is between 2.7 (the low range value shown incolumn 12) and 3.6 (the high range value shown in column 13). A bloodchemical reading below the optimum Severity Range results in a minimumrange of 1.6 and a maximum ranges of 2.6 and as shown in 18 and 19 ofTable 3 respectively.

Table 2 is a sample of a Canine Dosage Chart. It should be appreciatedthat Table 2 shows only a portion of the Canine Dosage Chart whichincludes enzymes/digestive aids and glandulars. A complete Dosage Chartmay also provide dosage information for a variety of vitamins, minerals,homeopathics, herbal supplements, and the like. Separate dosage chartsmay be provided for each type of animal. Using the appropriate DosageChart (e.g., Table 3 for a canine), the corresponding neutraceuticals inthe appropriate severity range are located and the Low Dosage 10 (Table2) is multiplied times 2 to get the High Dosage Multiplier as shown in17 (Table 3). This results in all the parts necessary to calculate theSlope 22 (as shown at step 4 of FIG. 2). Slope is a term used toindicate the slope of a line created by the relationship between thehighest and lowest severity points and the highest and lowest dosages.Slope is calculated by subtracting the Low Dosage from the High Dosageand dividing that number by the Minimum Range Value subtracted from theMaximum Range Value. The resulting equation reads:

Slope=(High Dosage−Low Dosage/Max Range Value−Min Range Value).

Continuing the canine example discussed above and using a liversupplement as an identified nutraceutical for a low albumin level (asdiscussed above in connection with Table 1), the Canine Dosage Chart(Table 2) indicates a low dosage (at column 10) for a liver supplementof 4.5. As the maximum dosage is the low dosage times 2, the maximumdosage for the liver supplement is 9. The multipliers for low and highdosages are shown in columns 16 and 17 of Table 3. Accordingly, for thecanine example under consideration, the high dosage multiplier is 9, thelow dosage multiplier is 4.5, the maximum range is 2.6 and the minimumrange is 1.6. Therefore, the slope may be calculated as:Slope=(9−4.5)/(2.6−1.6)=4.5, as indicated in column 14 of Table 3.

Using Slope, it can be determined where the actual blood chemicalreading falls in relationship to the Low Dosage and the High Dosage bysubtracting the Maximum Range Value from the Blood Chemical Reading andmultiplying that number times the Slope. The result is then added to theHigh Dosage to get the Strength 23 (as shown in step 5 of FIG. 2). Theresulting equation reads:

Strength=Slope×(Blood Chemical Reading−Max Range Value)+High DosageMultiplier.

For the above-referenced canine example, the strength may be calculatedas: Strength=4.5(2−2.6)+9=6.3.

To determine the Pre-Cap Dosage Amount 24 (as shown in step 6 of FIG.2), multiply Strength times the Weight of the animal. The Pre-Cap Dosageis defined as the dosage before the High Cap or Low Cap is applied. Theresulting equation reads:

Pre-Cap Dosage Amount=Strength×Animal Weight.

The canine example shown in FIG. 2 indicates that the weight of thecanine is 75 lbs. Therefore, the Pre-Cap Dosage Amount for this caninemay be calculated as:

Pre-Cap Dosage Amount=6.3×75=472.5.

The Pre-Cap Dosage Amount is then compared to the Low Cap 26 and HighCap 25 shown in Table 2. If the amount is lower than the Low Cap thenthe actual Dosage Amount is equal to the Low Cap (step 7). If the amountis greater than the High Cap (step 8) then the actual Dosage Amount isequal to the High Cap. If the amount is between the High Cap 25 and theLow Cap 26, the actual dosage amount is equal to the Pre-Cap DosageAmount.

As shown in columns 25 and 26 of Table 2 for the canine example, theHigh Cap for the liver supplement is 600 and the Low Cap is 60. ThePre-Cap dosage for the canine computed above is 472.5, which fallsbetween the indicated High and Low Cap values shown on Table 2.Therefore, the Pre-Cap Dosage Amount will be the actual dosage amount inthis canine example.

The process discussed above and shown in FIG. 2 is repeated for eachblood parameter that falls outside of the optimal range established forthat parameter, and for each nutraceutical identified for each of theseblood parameters that are outside of the normal range (step 9 of FIG.2). Table 5 below shows an example of calculated dosages for therequired nutraceuticals determined by the present invention in responseto the blood test results listed in Table 1 above.

TABLE 5 Calculated dosages of prescribed nutraceuticals Dosage GlandularSupplements Bone Marrow 175 mg Ovary/Uterus 250 mg Adrenal 150 mg Kidney200 mg Liver 472.5 mg Pituitary Whole 125 mg Medicinal Supplements SOD100 mg Mineral Supplements Trace Minerals 50 mg Nutrients I-acidmicrobials 0.05 units I-carintine 50 mg Lecithin Inositol Choline 250 mgTaurine 85 mg Vitamin Supplements Vitamin A/D 1250 iu Vitamin B Acid 85mg Vitamin B6 80 mg Vitamin C Complex 550 mg Vitamin E 225 iu LIQUIDREMEDIES Female Drops 13 drops BID-OA Female Formula 17 drops BIDIncontinence Drops 13 drops BID-OA Kidney/Bladder Formula 17 dropsBID-OA Kidney/Ovarian/Adrenal Drops 13 drops BID-OA Pituitary Drops 13drops BID-OA

The liquid remedies are custom blended formulas designed to addressspecific problems. Female Drops provide specific cellular, tissue andmetabolic support for the ovaries, uterus and imbalances related to thefemale hormonal system (especially in spayed females). Female Formula isdesigned to help balance female hormones, and tone strengthen theproductive system. Relieves ovarian and uterine pain and inflammation.In spayed females, it will help balance the other glands that areinvolved in female hormone production. Incontinence Drops providehomeopathic support for the urinary bladder and sphincter to improvecontrol for urinary leakage. Kidney/Bladder Formula reduces inflammationand strengthens the entire urinary tract in conditions such as lowerurinary tract disease (LUTD), nephritis, cystitis, urolithiasis andurethritis. Kidney/Ovarian/ Adrenal Drops provide specific cellular andglandular support for the kidney, ovary and adrenal glands. PituitaryDrops provide tissue and glandular support for the pituitary gland.

It should now be appreciated that the present invention providesadvantageous methods and systems for providing a nutraceutical programspecific to an individual animal, which determines appropriate dosagesof nutraceuticals for optimization of the animal's health.

Although the invention has been described in connection with variousillustrated embodiments, numerous modifications and adaptations may bemade thereto without departing from the spirit and scope of theinvention as set forth in the claims.

1. A method of providing a nutraceutical program specific to anindividual animal, comprising: drawing blood from the animal; analyzingthe blood at a lab to obtain blood test results; scoring the blood testresults to obtain at least one blood test score for at least onecorresponding blood parameter; determining if the at least one bloodtest score falls outside a normal range defined for the correspondingblood parameter; and if said at least one blood test score falls withinsaid normal range but outside of an optimal range within said normalrange: identifying one or more nutraceuticals needed to bring the animalwithin the optimal range for the at least one corresponding bloodparameter; and calculating a prescribed dosage amount for at least oneof said one or more identified nutraceuticals for the animal based on atleast said blood test score for said corresponding blood parameter and adeviation of the blood test score from the optimal range; if said atleast one blood test score falls outside of said normal range:prescribing standard nutrients or medications in order to bring the atleast one blood test score within said normal range.
 2. A method inaccordance with claim 1, wherein said animal comprises a human.
 3. Amethod in accordance with claim 1, wherein said animal comprises one ofa fish, an amphibian, a reptile, a bird, or a mammal.
 4. A method inaccordance with claim 1, wherein said animal belongs to one of thefollowing groups of animals: livestock, cattle, pets, domesticatedanimals, zoo animals, or exotic animals.
 5. A method in accordance withclaim 1, wherein said identifying of said one or more nutraceuticals isbased on at least one of animal type, animal physiology, animalbiochemistry, data describing an observed physical condition of theanimal, and data describing a medical diagnosis of the animal.
 6. Amethod in accordance with claim 1, wherein the calculating of theprescribed dosage amount for a particular identified nutraceuticalcomprises: calculating a pre-cap dosage amount based on said blood testscore, said deviation of the at least one blood test score from theoptimal range, animal type, animal weight, dosage strength information,and dosage limit information; and comparing said calculated pre-capdosage amount to a low-cap dosage amount and a high-cap dosage amountfor the animal; wherein: if the pre-cap dosage amount is between thelow-cap and high-cap dosage amounts, the prescribed dosage amount isequal to the pre-cap dosage amount; if the pre-cap dosage amount isgreater than the high-cap dosage amount, the prescribed dosage amount isequal to the hi-cap dosage amount; and if the pre-cap dosage amount isless than the low-cap dosage amount, the prescribed dosage amount isequal to the low-cap dosage amount.
 7. A method in accordance with claim6, wherein: the low-cap dosage amount is the minimal amount of anidentified nutraceutical prescribed for an animal regardless of theanimal weight or the deviation of the at least one blood test score fromthe optimal range; and the high-cap dosage amount is the maximum amountof an identified nutraceutical prescribed for an animal regardless ofthe animal weight or the deviation of the at least one blood test scorefrom the optimal range.
 8. A method in accordance with claim 6, whereinsaid pre-cap dosage amount is equal to a dosage strength S times theweight of the animal.
 9. A method in accordance with claim 8, whereinsaid dosage strength S is defined as:S=slope(blood test score−maximum range value)+High dosage.
 10. A methodin accordance with claim 9, further comprising: establishing a pluralityof severity levels indicating a range of blood test scores which deviatefrom said optimal range; wherein a negative severity level indicates arange of blood test scores below a minimum of said optimal range, and apositive severity level indicates a range of blood test scores above amaximum of said optimal range.
 11. A method in accordance with claim 10,wherein: if the at least one blood test score falls within a negativeseverity level: the maximum range value is the highest value of thenegative severity level closest to said optimal range; and a minimumrange value is the lowest value of the negative severity level furthestfrom said optimal range; and if the at least one blood test score fallswithin a positive severity level: the maximum range value is the highestvalue in the positive severity level furthest from said optimal range;and the minimum range value is the lowest value in the positive severitylevel closest to said optimal range.
 12. A method in accordance withclaim 11, wherein slope is defined as:slope=(high dosage−low dosage)/(said maximum range value−said minimumrange value).
 13. A method in accordance with claim 12, wherein: saidlow dosage indicates a minimum nutraceutical strength prescribed for ananimal regardless of the animal weight or the severity level of said atleast one blood test score; and said high dosage is approximately doublesaid low dosage.
 14. A method in accordance with claim 1, wherein atleast one of said normal range and said optimal range is derived from adatabase containing historical blood test scores for a plurality ofanimals.
 15. A method in accordance with claim 14, wherein said databaseis updated with information regarding animal type, animal weight andblood test scores obtained from testing of various animals.
 16. A methodin accordance with claim 1, wherein said blood parameters comprise atleast one of white blood cell information, red blood cell information,and blood chemistry information.
 17. A method in accordance with claim1, wherein said blood parameters correspond to the function of one ormore organs of the animal.
 18. A method in accordance with claim 1,wherein the nutraceuticals comprise at least one of vitamins, minerals,enzymes, amino acids, homeopathic supplements, herbal supplements, andraw glandular supplements.
 19. A method in accordance with claim 1,wherein: the blood test results are electronically communicated from thelab to a service provider; the service provider scores the blood testresults to obtain the at least one blood test score and calculates theprescribed dosage amounts; the prescribed dosage amounts areelectronically communicated from the service provider to a compoundpharmacist; and the compound pharmacist prepares a prescriptioncontaining the one or more identified nutraceuticals in accordance withthe prescribed dosage amounts and ships the prescription to an owner orveterinarian for administration to the animal.